Neurizon Therapeutics (ASX:NUZ) Long-Term Capital Lease Obligation: A$0.00 Mil (As of Dec. 2025)


What is Neurizon Therapeutics Long-Term Capital Lease Obligation?

Neurizon Therapeutics ASX:NUZ Long-Term Capital Lease Obligation is A$0.00 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Neurizon Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Neurizon Therapeutics's annual Long-Term Capital Lease Obligation declined from Jun. 2023 (A$0.89 Mil) to Jun. 2024 (A$0.00 Mil) but then stayed the same from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Neurizon Therapeutics  (ASX:NUZ) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Neurizon Therapeutics Long-Term Capital Lease Obligation Related Terms

Neurizon Therapeutics Long-Term Capital Lease Obligation Historical Data

* Premium members only.

The historical data trend for Neurizon Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics Long-Term Capital Lease Obligation Chart

Neurizon Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 1.04 0.89 0.00 0.00

Neurizon Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a Long-Term Capital Lease Obligation of A$0.00 Mil mean?
Neurizon Therapeutics (ASX:NUZ) has a Long-Term Capital Lease Obligation of A$0.00 Mil as of Dec. 2025. Capital leases are leases where a finance company is typically the legal owner of the asset during the lease term. View historical data on Neurizon Therapeutics and its competitors.
Is Neurizon Therapeutics' Long-Term Capital Lease Obligation too high?
Neurizon Therapeutics' current Long-Term Capital Lease Obligation is A$0.00 Mil.
How does Neurizon Therapeutics' Long-Term Capital Lease Obligation compare to VRTX and REGN?
Neurizon Therapeutics' Long-Term Capital Lease Obligation of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Capital Lease Obligation for a Biotechnology company?
A good Long-Term Capital Lease Obligation depends on the Biotechnology industry context. However, Long-Term Capital Lease Obligation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Capital Lease Obligation mean?
A high Long-Term Capital Lease Obligation can signal that a stock is expensive relative to its fundamentals. Capital leases are leases where a finance company is typically the legal owner of the asset during the lease term. View historical data on Neurizon Therapeutics and its competitors. Neurizon Therapeutics's current Long-Term Capital Lease Obligation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (ASX:NUZ) has a current Long-Term Capital Lease Obligation of A$0.00 Mil. The current Long-Term Capital Lease Obligation is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Capital Lease Obligation calculated?
Long-Term Capital Lease Obligation is calculated from a company's financial statements. For Neurizon Therapeutics (ASX:NUZ), the current Long-Term Capital Lease Obligation is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:Germany
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).